Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL V - Basal Insulin Switch)

Next Previous
X
Search
Trial Profile

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL V - Basal Insulin Switch)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec/liraglutide (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL V
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 29 Jun 2021 Results of post hoc analysis of two trials (DUAL V and DUAL VIII) comparing derived time in range with insulin degludec/liraglutide and insulin glargine 100 units/mL, presented at the 81st Annual Scientific Sessions of the American Diabetes Association
    • 08 Nov 2019 Results of post hoc analysis of two trials (DUAL V and DUAL VII) were published in the Diabetic Medicine
    • 23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top